Allergies are the 6th leading cause of chronic illness in the USA with an annual cost in excess of $18 billion. More than 50 million Americans suffer from allergies each year.
Immunotherapy has been shown to be an effective remedy against several types of allergies. User experience as well as theories based on animal studies indicate a possible powerful role for AndoSan™ in treatment of allergies.
Doctors at Oslo University Hospital, led by Dr. Hetland, in spring 2016 conducted a clinical study on the use of AndoSan™ in blood donors with pollen allergy and/or asthma. A total of sixty patients were included, of whom 30 were randomized to receive AndoSan™ for three weeks ahead of the pollen season, while the remaining 30 patients received placebo. The patient phase has been finished and data has been sent for analysis. The trial has been looking at several parameters including basophilic activation test, antigens, cytokines as well as quality of life. Preliminary results, revealed to ImmunoPharma in confidence, looks very promising. The trial is expected to result in four scientific publications that will form the basis for a PhD degree.